SGLT2 from a cardiologist point of view...

Description

Outline -Direct Effects ofSGLT2 on the Cardiomyocyte -Hospitalisation for Heart Failure -EMPA-REG outcome - Story of SGLT2 inhibition in heart failure. -Summary of CV and renal end points HR in CVOT testing SGLTi in patients with or without diabetes. -CV death -Major end points in SGLTi Cardiovascular outcome trials in patients with T2DM

Objectives

Presenters

1. Dr. Bernard Gitura
   MMED, FACC, FESC Consultant Cardiologist
   Kenyatta National Hospital


2. Dr. Anthony Gikonyo
   Interventional Cardiologist
   Karen Hospital, Nairobi